A revolutionary microarray immunoassay enables patients to receive results for multiple allergens using just a single blood sample, thereby minimizing the necessity for multiple tests and appointments.

AliveDx’s (Eysins, Switzerland) groundbreaking microarray immunoassay is specifically designed to detect specific IgE antibodies directed against protein allergens in human serum and runs on the company’s proprietary MosaiQ platform. This multiplex immunoassay microarray is capable of detecting over 30 allergens, including those from both inhalants and foods and represents a significant leap in diagnostic capabilities by allowing simultaneous testing for various conditions. This method streamlines the diagnostic process, simplifies laboratory workflows, and reduces the manual labor typically associated with singleplex testing methods. Consequently, it saves significant time for both laboratories and clinicians, enhancing the ability to efficiently diagnose and exclude multiple conditions. For patients who are sensitized to multiple allergens, this technology offers a rapid, comprehensive diagnostic process and supports more targeted treatment approaches.

AliveDx has now received the IVDR CE mark for its microarray immunoassay while the MosaiQ platform is already CE-marked for autoimmune disease screening. This first IVDR CE mark in the allergy category reaffirms AliveDx's commitment to broadening the reach of its MosaiQ platform and to supporting the millions globally who suffer from allergies. This milestone also reinforces the company’s role as a major player in both the allergy and autoimmune markets and highlights the MosaiQ platform’s flexibility and versatility. Going forward, AliveDx plans to expand its panels in both areas and to partner with distributors worldwide.

"The new multiplex immunoassay will provide a detailed analysis of an individual's allergic sensitization by testing specific IgE to a wide array of allergens in a single test," said Christian Fischer, Chief Scientific & Medical Officer at AliveDx. “This comprehensive approach will help optimize laboratory workflows, and help clinicians obtain a complete picture of their patient's atopic sensitization profile.”

“Patients will soon be able to receive results for multiple allergens from a single blood sample, reducing the need for multiple tests and visits,” added Manuel O. Méndez, CEO of AliveDx. “For the medical community, this means having access to an efficient and cost-effective solution, which consolidates multiple tests into one. We look forward to supporting patients around the world, and helping them get appropriate treatment sooner."

Source:

https://www.labmedica.com/molecular-diagnostics/articles/294802024/groundbreaking-microarray-immunoassay-simultaneously-detect-30-allergens-from-single-blood-sample.html